A fresh look at glucocorticoids: How to use an old ally more effectively

Bulletin of the NYU Hospital for Joint Diseases

Volumn 70, Issue SUPPL. 1, 2012, Pages

  Buttgereit, Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CYTOKINE; DIPYRIDAMOLE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; INTERLEUKIN 6; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; AWARENESS; CHRONOTHERAPY; DELAYED DRUG RELEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; FATIGUE; HUMAN; IMMOBILIZATION; JOINT DESTRUCTION; LOW DRUG DOSE; PAIN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RIGIDITY; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHRONOTHERAPY; GLUCOCORTICOIDS; HUMANS; PREDNISONE; TREATMENT OUTCOME;

EID: 84872786999     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Buttgereit F. Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? Ann Rheum Dis. 2011 Nov;70(11):1881-1883.
2. Neovius M, Simard JF, Askling J. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis. 2011 Apr;70(4):624-629.
3. Buttgereit F. Current issues of basic and clinical glucocorticoid research. Clin Exp Rheumatol. 2003 Mar-Apr;21(2):145-147.
4. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum. 1998 May;41(5):761-767.
5. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glu-cocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004 Nov;50(11):3408-3417.
6. Rhen T, Cidlowski JA. Antiinflammatory action of glucocor-ticoids--new mechanisms for old drugs. N Engl J Med. 2005 Oct 20;353(16):1711-1723.
7. Stahn C, Buttgereit F. Genomic and nongenomic effects of glu-cocorticoids. Nat Clin Pract Rheumatol. 2008 Oct;4(10):525-533.
8. van de Goes M, Jacobs J, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recom-mendations for clinical trials and daily practice. Ann Rheum Dis. 2010 Nov;69(11):1913-1919.
9. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocor-ticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007 Dec;66(12):1560-1567.
10. Buttgereit F, Burmester GR, Straub RH, et al. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum. 2011 Jan;63(1):1-9.
11. Zimmermann GR, Avery W, Finelli AL, et al. Selective ampli-ficationof glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res Ther. 2009;11(1):R12.
12. Rauchhaus U, Kinne RW, Pohlers D, et al. Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis. Ann Rheum Dis. 2009 Dec;68(12):1933-1934.
13. Buttgereit F, Doering G, Schaeffer A, et al. Efficacy of modified-release versus standard prednisone to reduce dura-tion of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008 Jan 19;371(9608):205-214.
14. Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007 Feb;56(2):399-408.
15. De Jongh RF, Vissers KC, Meert TF, et al. The role of in-terleukin-6 in nociception and pain. Anesth Analg. 2003 Apr;96(4):1096-1103.
16. Arvidson NG, Gudbjornsson B, Elfman L, et al. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis. 1994 Aug;53(8):521-524.
17. Buttgereit F, Doering G, Schaeffer A, et al. Targeting patho-physiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010 Jul; 69(7):1275-1280.
18. Alten R, Döring G, Cutolo M, et al. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol. 2010 Oct; 37(10):2025-2031.
19. Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2012 May 5. [Epub ahead of print] PubMed PMID: 22562974.
20. Buttgereit F, Burmester GR, Lipworth BJ. Optimised glu-cocorticoid therapy: the sharpening of an old spear. Lancet. 2005;365(9461):801-803.